Immunosuppressive monoclonal antibodies: Current and next generation

  • Focosi D
  • Maggi F
  • Pistello M
 et al. 
  • 45

    Readers

    Mendeley users who have this article in their library.
  • 6

    Citations

    Citations of this article.

Abstract

Monoclonal antibodies (mAbs) are well-established therapeutics, as evidenced by the large number of Food and Drug Administration-approved mAbs for the treatment of cancers, and inflammatory or autoimmune diseases, and for the prevention and treatment of solid organ transplant rejection. Although, in many cases, mAbs have improved patient survival, they are also associated with an increased incidence of opportunistic infections. We review here the current and next generation of mAbs and the risks that infectious disease specialists should be aware of.

Author-supplied keywords

  • Antibody
  • Immunosuppression
  • Infectious diseases
  • Monoclonal antibody
  • Opportunistic infections

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • D. Focosi

  • F. Maggi

  • M. Pistello

  • U. Boggi

  • F. Scatena

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free